07c9c36f-e6df-464c-91fb-c1bbf7045a42
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 70.4969199178645
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.470
- OXIDATIVE_PHOSPHORYLATION+0.400
- WNT_BETA_CATENIN_SIGNALING+0.350
- P53_PATHWAY+0.340
- FATTY_ACID_METABOLISM+0.330
- PANCREAS_BETA_CELLS+0.330
- INTERFERON_GAMMA_RESPONSE+0.310
- CHOLESTEROL_HOMEOSTASIS+0.300
- PEROXISOME+0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.290
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.320
- UV_RESPONSE_DN-0.290
- ANGIOGENESIS-0.270
- MYOGENESIS-0.230
- PROTEIN_SECRETION-0.180
- MITOTIC_SPINDLE-0.090
- SPERMATOGENESIS-0.080
- APICAL_SURFACE-0.050
- TNFA_SIGNALING_VIA_NFKB-0.050
- HYPOXIA+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 4fc05c1a-63b9-415b-ad42-68b013e21b21 | — | — | 0.791 |
| 2 | 0F797735-CCCA-4BEA-BB94-C524E7D0A875 | — | — | 0.763 |
| 3 | 7a458b19-1b7c-422c-b900-cd77e5009421 | — | — | 0.758 |
| 4 | E775874C-4CE0-4D23-8CF0-7A3D72A84DD9 | — | — | 0.736 |
| 5 | 4f2a0f62-df55-4972-aeb4-fb32e6c9a522 | — | — | 0.736 |
| 6 | cddceb59-733b-48d1-9b75-46c9949f7794 | — | — | 0.729 |
| 7 | bc895549-854b-484f-8a6d-9e5152829bcb | — | — | 0.728 |
| 8 | 85EE23A9-B5E4-49F7-A504-CEF2EB4E4E7E | — | — | 0.726 |
| 9 | 46AD8592-A823-48DA-AB51-3CEC34F53E04 | — | — | 0.722 |
| 10 | BS_VF5XWFXD | high-grade glioma | — | 0.721 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.470 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.350 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.340 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.330 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.330 | Cobimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.310 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.300 | Remibrutinib | — uncovered |
| PEROXISOME | 0.300 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.290 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.290 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.280 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.280 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.260 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.200 | Idelalisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.180 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.160 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.160 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.140 | Idelalisib | — uncovered |